title: Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.
abstract: Trypanosoma cruzi is an intracellular parasite and the causative agent of Chagas disease. Previous work has shown that the chemokine receptor CCR5 plays a role in systemic T. cruzi protection. We evaluated the importance of CCR5 and CCL5 for mucosal protection against natural oral and conjunctival T. cruzi challenges. T. cruzi-immune CCR5(-/-) and wild-type C57BL/6 mice were generated by repeated infectious challenges with T. cruzi. CCR5(-/-) and wild-type mice developed equivalent levels of cellular, humoral, and protective mucosal responses. However, CCR5(-/-)-immune mice produced increased levels of CCL5 in protected gastric tissues, suggesting compensatory signaling through additional receptors. Neutralization of CCL5 in CCR5(-/-)-immune mice resulted in decreased mucosal inflammatory responses, reduced T. cruzi-specific Ab-secreting cells, and significantly less mucosal T. cruzi protection, confirming an important role for CCL5 in optimal immune control of T. cruzi replication at the point of initial mucosal invasion. To investigate further the mechanism responsible for mucosal protection mediated by CCL5-CCR5 signaling, we evaluated the effects of CCL5 on B cells. CCL5 enhanced proliferation and IgM secretion in highly purified B cells triggered by suboptimal doses of LPS. In addition, neutralization of endogenous CCL5 inhibited B cell proliferation and IgM secretion during stimulation of highly purified B cells, indicating that B cell production of CCL5 has important autocrine effects. These findings demonstrate direct effects of CCL5 on B cells, with significant implications for the development of mucosal adjuvants, and further suggest that CCL5 may be important as a general B cell coactivator.
authors.affiliation: Department of Molecular Microbiology and Immunology, Saint Louis University Medical Center, St. Louis, MO 63104, USA.
authors.forename: Nicole L
authors.initials: NL
authors.lastname: Sullivan
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Eickhoff
authors.forename: Xiuli
authors.initials: X
authors.lastname: Zhang
authors.forename: Olivia K
authors.initials: OK
authors.lastname: Giddings
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Lane
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Hoft
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology* / Q000469:parasitology / Q000473:pathology; D014355:Chagas Disease / Q000276:immunology* / Q000378:metabolism / Q000469:parasitology; D018946:Chemokine CCL5 / Q000096:biosynthesis / Q000502:physiology*; D005260:Female; D005753:Gastric Mucosa / Q000276:immunology* / Q000469:parasitology / Q000473:pathology; D005786:Gene Expression Regulation / Q000276:immunology; D006801:Humans; D056965:Injections, Intraocular; D008213:Lymphocyte Activation / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009061:Mouth Mucosa / Q000276:immunology* / Q000469:parasitology / Q000473:pathology; D019713:Receptors, CCR5 / Q000096:biosynthesis / Q000172:deficiency / Q000502:physiology*; D014349:Trypanosoma cruzi / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity
chemical_list: D018946:Chemokine CCL5; D019713:Receptors, CCR5